Literature DB >> 14645655

Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective.

Graeme Milligan1.   

Abstract

Over the last decade, the ability to detect agonist-independent signal transduction by G protein-coupled receptors has in turn resulted in the detection and study of ligands able to block this activity. Such ligands are generically described as inverse agonists. Considerable attention has recently been devoted to the presence and roles of endogenous antagonist/inverse agonists and the concept that inverse agonists may have specific therapeutic benefits compared with neutral antagonists.

Mesh:

Substances:

Year:  2003        PMID: 14645655     DOI: 10.1124/mol.64.6.1271

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  78 in total

1.  Insights into the Basal Activity and Activation Mechanism of the β1 Adrenergic Receptor Using Native Mass Spectrometry.

Authors:  Agni F M Gavriilidou; Hanna Hunziker; Daniel Mayer; Ziva Vuckovic; Dmitry B Veprintsev; Renato Zenobi
Journal:  J Am Soc Mass Spectrom       Date:  2018-12-03       Impact factor: 3.109

Review 2.  The significance of G protein-coupled receptor crystallography for drug discovery.

Authors:  John A Salon; David T Lodowski; Krzysztof Palczewski
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

3.  Superactive mutants of thromboxane prostanoid receptor: functional and computational analysis of an active form alternative to constitutively active mutants.

Authors:  Manuela Ambrosio; Francesca Fanelli; Silvia Brocchetti; Francesco Raimondi; Mario Mauri; G Enrico Rovati; Valérie Capra
Journal:  Cell Mol Life Sci       Date:  2010-04-11       Impact factor: 9.261

4.  CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.

Authors:  Sven Jähnichen; Christophe Blanchetot; David Maussang; Maria Gonzalez-Pajuelo; Ken Y Chow; Leontien Bosch; Sindi De Vrieze; Benedikte Serruys; Hans Ulrichts; Wesly Vandevelde; Michael Saunders; Hans J De Haard; Dominique Schols; Rob Leurs; Peter Vanlandschoot; Theo Verrips; Martine J Smit
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

Review 5.  New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma.

Authors:  J K L Walker; R B Penn; N A Hanania; B F Dickey; R A Bond
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

6.  Homeostatic scaling requires group I mGluR activation mediated by Homer1a.

Authors:  Jia-Hua Hu; Joo Min Park; Sungjin Park; Bo Xiao; Marlin H Dehoff; Sangmok Kim; Takashi Hayashi; Martin K Schwarz; Richard L Huganir; Peter H Seeburg; David J Linden; Paul F Worley
Journal:  Neuron       Date:  2010-12-22       Impact factor: 17.173

7.  Agonism, Antagonism, and Inverse Agonism Bias at the Ghrelin Receptor Signaling.

Authors:  Céline M'Kadmi; Jean-Philippe Leyris; Lauriane Onfroy; Céline Galés; Aude Saulière; Didier Gagne; Marjorie Damian; Sophie Mary; Mathieu Maingot; Séverine Denoyelle; Pascal Verdié; Jean-Alain Fehrentz; Jean Martinez; Jean-Louis Banères; Jacky Marie
Journal:  J Biol Chem       Date:  2015-09-11       Impact factor: 5.157

Review 8.  Identifying ligands at orphan GPCRs: current status using structure-based approaches.

Authors:  Tony Ngo; Irina Kufareva; James Lj Coleman; Robert M Graham; Ruben Abagyan; Nicola J Smith
Journal:  Br J Pharmacol       Date:  2016-03-05       Impact factor: 8.739

Review 9.  Oligomerization of G protein-coupled receptors: past, present, and future.

Authors:  Paul S-H Park; Slawomir Filipek; James W Wells; Krzysztof Palczewski
Journal:  Biochemistry       Date:  2004-12-21       Impact factor: 3.162

10.  A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators.

Authors:  Sandra Claes; Thomas D'huys; Anneleen Van Hout; Dominique Schols; Tom Van Loy
Journal:  J Vis Exp       Date:  2018-02-20       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.